Content Block Tag: NRG-GY002
‘NRG-GY002 Documentation’ of page ‘NRG-GY002’
Action Letter (posted 2/3/17) and Amendment 3 documents (posted 2/13/17) Action Letter – Nivolumab GY002 Amendment 3 GY002 Amendment 3 w/ Tracked changes GY002 Informed Consent GY002 Informed Consent w/ Tracked changes Broadcast Memo (8/29/16) GY002 Data Management Transition Closure Documents (6/8/16) GY002 Closure GY002 Closure w/ Tracked changes Reactivation and Amendment 2 Documents ( […]
Read More
‘NRG-GY002: A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer’ of page ‘NRG-GY002’
Principal Investigator/Co-Principal Investigator Alessandro D. Santin, M.D./Michael Fromovitz, M.D., M.P.H. Primary Objective To assess the antitumor activity (proportion of objective response by RECIST 1.1 criteria) of Nivolumab with objective tumor response in patients with persistent, recurrent or metastatic carcinoma of the cervix, and to determine the nature and degree of toxicity of nivolumab as assessed […]
Read More